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Abstract
Thromboembolism is a common and deadly consequence of COVID-19 infection for hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and early observational reports, expert consensus and guidance documents have strongly encouraged the use of prophylactic anticoagulation for patients hospitalized for COVID-19 infection.
More recently, multiple clinical trials and larger observational studies have provided evidence for tailoring the approach
to thromboprophylaxis for patients with COVID-19. This document provides updated guidance for the use of anticoagulant therapies in patients with COVID-19 from the Anticoagulation Forum, the leading North American organization of
anticoagulation providers. We discuss ambulatory, in-hospital, and post-hospital thromboprophylaxis strategies as well as
provide guidance for patients with thrombotic conditions who are considering COVID-19 vaccination.
Keywords Anticoagulation · COVID-19 · Direct oral anticoagulant · Prophylaxis · Stewardship · Venous
thromboembolism · Direct-acting oral anticoagulant · Low-molecular-weight heparin · Enoxaparin · rivaroxaban ·
Aspirin · Thrombosis and thrombocytopenia syndrome · Pregnancy · Thrombophilia

Introduction and background
Early in the coronavirus disease 2019 (COVID-19) pandemic, thrombosis was identified as a key associated complication. Without the benefit of high-quality evidence,
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numerous expert guidance documents were published
addressing the intensity of thromboprophylaxis in the hospital and non-hospital setting, the role of biomarkers to guide
antithrombotic therapy, and best practices for minimizing
COVID-19 exposure for patients on chronic anticoagulant
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Table 1 Summary of Guidance Recommendations
Clinical Area
Adult patients
Thromboembolic Prevention
- Ambulatory

Recommendation

We recommend against any specific antithrombotic preventative therapy for ambulatory (non-hospitalized) adult patients
with mild COVID-19 infection who have no other indication for antithrombotic therapy.
We recommend patients on antithrombotic therapy prior to diagnosis of COVID-19 continue their antithrombotic therapy
unless a significantly elevated risk of bleeding has developed
Thromboembolic We recommend that all patients hospitalized with COVID-19 receive at least standard dose thromboprophylaxis.
Prevention – Hos- We suggest that non-heparin anticoagulants (i.e., direct oral anticoagulants) be avoided when therapeutic intensity thrompitalized (all)
boprophylaxis is utilized.
We recommend that “intermediate” intensity thromboprophylaxis and/or antiplatelet agents only be used in the setting of
a clinical trial for hospitalized patients with COVID-19.
We suggest that adult patients admitted to the hospital for COVID-19 remain on the intensity of VTE thromboprophylaxis
that was initiated at hospital admission as long as their bleeding risk is not significantly elevated.
In patients admitted to the hospital for indications other than COVID-19 but incidentally found to have COVID-19 infection, we recommend standard dose thromboprophylaxis with LMWH or UFH unless specific contraindications exist.
We suggest that the use of adjunctive therapies (i.e., statins, antiplatelets) only be used in the setting of a clinical trial.
Thromboembolic We suggest that clinicians consider the use of therapeutic intensity LMWH or UFH thromboprophylaxis for non-critically
Prevention –
ill patients at increased risk of disease progression or thromboembolism and who are not high risk for anticoagulantHospitalized (non- related bleeding (Table 2).
critically ill)
ThromboemWe recommend that adult patients who are critically ill at the time of hospitalization receive standard dose thromboprobolic Prevention
phylaxis instead of intermediate- or therapeutic intensity thromboprophylaxis.
– Hospitalized
(critically ill)
ThromboemWe recommend that clinicians not routinely use post-hospital thromboprophylaxis after discharge following hospitalbolic Prevention
ization for COVID 19 for all patients, including those who may have received therapeutic intensity anticoagulation for
– Post-hospital
thromboprophylaxis.
We suggest post-hospital thromboprophylaxis with rivaroxaban 10 mg daily for 35 days following a hospitalization for
COVID-19 may be considered in select patients at increased risk of thromboembolism (e.g., IMPROVE VTE score ≥ 4
or score 2–3 with elevated D-dimer) and not at increased risk of bleeding regardless of the intensity of their inpatient
thromboprophylaxis.
We recommend clear documentation and communication of indication and intended duration of post-hospital thromboprophylaxis to providers and next care settings to avoid unnecessarily prolonged exposure to anticoagulation.
VTE Treatment
We recommend that most patients who are diagnosed with VTE while hospitalized for COVID-19 receive anticoagulation
for a minimum of three to six months, in accordance with recent guidelines for VTE with a transient provoking risk factor.
We suggest a finite course of anticoagulation (e.g., 3–6 months) rather than continuing anticoagulation long-term for secondary prevention in most patients with COVID-19 associated VTE. The duration should be a minimum of three months
and defined by the presence or absence of persistent risk factors and the patients’ return to their baseline functional status.
COVID-19
We recommend that all patients with a history of thromboembolism, thrombophilia, or current use of anticoagulation be
Vaccination
offered and encouraged to receive COVID-19 vaccination.
We recommend that anticoagulation not be withheld for vaccine administration.
If a patient currently uses anticoagulant therapy, we recommend that pressure be held at the site of vaccine administration
for 5 min to minimize any risk of injection-related bleeding.
We recommend that standard warfarin monitoring schedules not be altered in relation to vaccine administration for most
patients. Individual patients experiencing significant symptoms, such as fever or dietary disruption, should contact their
prescriber to determine if additional INR follow up is warranted.
Pediatric patients
We suggest that clinicians consider thromboprophylaxis with twice daily LMWH (e.g., enoxaparin 0.5 mg/kg BID)
targeted to an anti-Xa activity level of 0.2 to < 0.5 IU/ml (in combination with mechanical prophylaxis when feasible) in
pediatric patients hospitalized with acute COVID-19 or MIS-C and one or more additional risk factors associated with
hospital-acquired VTE (e.g., central venous catheter, age > 12 years, immobility, mechanical ventilation, history of VTE,
obesity, active malignancy, etc.) OR markedly elevated D-dimer, as long as the patient is not high risk for bleeding.
We recommend against thromboprophylaxis in hospitalized children who are incidentally found to have asymptomatic
SARS-CoV-2 in the absence of other VTE risk factors that would normally merit prophylaxis.
Because of very limited published evidence, we suggest that post-discharge thromboprophylaxis be considered on a caseby-case basis in highly select pediatric patient with multiple ongoing risk factors.
Obstetric patients
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Table 1 (continued)
Clinical Area

Recommendation
We recommend against routine thromboprophylaxis for pregnant women found to be COVID-19 positive and not requiring admission to the hospital. Patients should be encouraged to stay hydrated and ambulate at home.
For pregnant women requiring hospitalization for COVID-19, we recommend use of thromboprophylaxis in accordance
with existing obstetric guidelines for non-COVID-19 positive women. Readers are referred to those population-specific
resources for thromboprophylaxis dosing recommendations that take into consideration trimester, as well as ante- and
post-partum needs.
For pregnant women already receiving anticoagulant prophylaxis or treatment prior to hospital admission for COVID-19,
we recommend continuing those therapies during admission and beyond if indicated.
We suggest against routine post-discharge prophylaxis for COVID-19 positive obstetric patients unless they otherwise
meet criteria for extended obstetric prophylaxis for non-COVID populations.
Other Special Populations
Long-term Care
We suggest that patients who reside in long-term care settings who are ill enough with COVID-19 to be considered for
Facilities
hospital admission but remain in the long-term care facility be offered standard intensity thromboprophylaxis (Table 3) for
up to 10–14 days only if this aligns with their goals of care.
Patients with
We recommend that all adult patients with a known thrombophilia receive at least standard intensity thromboprophylaxis
Thrombophilia
when hospitalized for COVID-19, unless already on chronic therapeutic-intensity anticoagulation for the thrombophilia.
Patients with antico-We recommend that patients who are admitted to the hospital for COVID-19 infection be assessed for the use of ongoing
agulation use prior outpatient anticoagulation.
to hospitalization We recommend that the outpatient anticoagulation regimen be continued during the hospitalization for COVID-19 unless
there are conditions that will preclude safe use (e.g., acute renal failure, anticipated invasive procedures, significant drugdrug interactions). Therapeutic or prophylactic UFH or LMWH may be substituted according to the clinical scenario. Dosing intensity of UFH or LMWH should take into consideration the underlying non-COVID indication for anticoagulation
as well as COVID-related thromboprophylaxis needs as described in the above recommendations.
We recommend that patients who were receiving reduced dose or very low dose anticoagulation (i.e., rivaroxaban 2.5 mg
twice daily) prior to admission and who are hospitalized for COVID-19 substitute either receive either standard dose or
therapeutic intensity thromboprophylaxis with LMWH or UFH as clinically appropriate (see recommendations above).
VTE – venous thromboembolism, ULN – upper limit of normal, ICU – intensive care unit, DOAC – direct oral anticoagulant, LMWH – lowmolecular-weight heparin, UFH – unfractionated heparin

therapy.[1–4] These documents were based largely on indirect evidence from non-COVID patients and relied on expert
opinion. Since then, evidence in the prevention and treatment
of COVID-19 has emerged. Clinical trials have addressed
vaccine efficacy and safety, the role of steroids and the
utility of numerous anti-viral therapies. Understanding of
pathophysiologic mechanisms of thrombosis in COVID-19
has evolved, with recognition that patients may be at risk for
both macrothrombotic events (e.g., deep venous thrombosis, pulmonary embolism) and immunothrombosis in situ. It
has been proposed that anticoagulants may have pleiotropic
antiviral and anti-inflammatory effects, in addition to thromboembolism prevention in hospitalized COVID-19 patients.
[5–7] In light of the emerging evidence, we provide updated
guidance for key areas of thromboembolism prevention and
treatment for patients with COVID-19 (Table 1).
COVID-19 vaccination dramatically reduces the risk
of severe infection, and therefore also greatly reduces the
risk of infection-associated thrombosis. Patients with prior
venous thromboembolism (VTE) may be leery of vaccination due to concerns that the immunization will increase the
risk of thrombosis. Providers should educate patients about
the thrombotic risk associated with COVID-19 infection and
emphasize that COVID-19 itself is likely to greatly accentuate their risk of thromboembolism orders of magnitude

greater than any potential thromboembolism risk following
vaccination.[8] A past history of venous thromboembolism
and enhanced risk for venous thromboemboli do not constitute a rationale for not being vaccinated.

Methods
As with previous Anticoagulation Forum guidance documents, we prioritized a set of key questions and/or clinical
practice areas relevant to thrombosis prevention and treatment among patients at risk for or diagnosed with COVID19. These questions and clinical practice topics were selected
through discussion and consensus among the authors as
well as by members of the Anticoagulation Forum through
an online survey (Table 1). We searched PubMed to identify
evidence related to these questions. This search was supplemented by articles from the authors’ files and manual review
of references. For each question or topic area, a summary of
the evidence is provided, followed by guidance representing
consensus of the authors.
Guidance statements with strong evidence-base or broad
expert consensus are described using the term “recommend.” Statements with less strong evidence or less consensus are described using “suggest.” As with all clinical
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guidance, these statements should not replace clinical judgement by the treating care team and review of evolving clinical evidence.

Thromboembolic Prevention – Adult NonPregnant Populations
Ambulatory Patients with COVID-19
For ambulatory (non-hospitalized) adult patients with
COVID-19, the overall risk of thromboembolism does not
appear to be markedly elevated.[9, 10] The National Institutes of Health (NIH)-sponsored ACTIV-4b clinical trial
comparing placebo, aspirin, and two doses of apixaban
for patients with COVID-19 infection who did not require
hospitalization was recently stopped due to a low number
of thromboembolic events across all treatment groups.
[11] Overall rates of death, symptomatic arterial or venous
thromboembolism, myocardial infarction, stroke, or cardiopulmonary hospitalization were extremely low in all groups
(0.7–1.4%) without any meaningful difference between
groups.
For patients who already take chronic antithrombotic
therapy (e.g., stroke prevention in atrial fibrillation, secondary prevention of coronary artery disease), observational studies have shown mixed results. Some have found
an association between use of antithrombotic agents and
improved outcomes while others have failed to demonstrate
such a benefit.[12, 13] Nonetheless, even in the presence
of COVID-19 infection, these patients usually retain their
indication for antithrombotic therapy. Therefore, unless
their clinical condition changes and the risk of bleeding significantly increases, continued use of the chronic antithrombotic agent is generally advised.
Guidance Recommendation:
1) We recommend against any specific antithrombotic
preventative therapy for ambulatory (non-hospitalized)
adult patients with mild COVID-19 infection who have
no other indication for antithrombotic therapy.
2) We recommend patients on antithrombotic therapy
prior to diagnosis of COVID-19 continue their antithrombotic therapy unless a significantly elevated risk
of bleeding has developed..

Non-Critically Ill Hospitalized Patients with
COVID-19
For adult patients who are not critically ill but still hospitalized for COVID-19 and do not otherwise have an indication for anticoagulation, four completed clinical trials have
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explored the potential role of different intensities of anticoagulation (online appendix). In the multiplatform clinical
trials (ATACC, ACTIV-4 A, REMAP-CAP) of more than
2200 patients, use of therapeutic-intensity heparin (primarily enoxaparin) was superior to ‘usual care’ pharmacologic
thromboprophylaxis (71.7% standard dose, 26.5% intermediate dose) with heparin (primarily low-molecular-weight
heparin [LMWH]) for increasing organ support-free days
which is the number of days without cardiovascular (e.g.
use of vasopressor or inotropic medications) or respiratory
(e.g. use of high-flow nasal cannula, noninvasive or invasive mechanical ventilation) support (80.2% vs. 76.4%,
adjusted difference 4.0%, 95% CI 0.5–7.2%).[14] Presence
of elevated baseline D-dimer did not significantly alter the
primary outcome. Overall survival until hospital discharge
was not different among the two treatment arms (adjusted
risk difference 1.3%, 95% CI − 1.1 to 3.2%), however there
was a reduction in the secondary outcome of major thromboembolic events or death (2.6%, 95% CI 0.2–4.4%) favoring therapeutic heparin. There was a numerically higher
risk of major bleeding with treatment-dose heparin (1.9%
vs. 0.9%) that did not reach statistical significance. Of
note, these trials screened more than 13,000 patients. Key
strengths of this trial are the large size, global site inclusion, and use of blinded adjudication of event outcomes. But
interpreting clinicians should be aware that > 12,000 of the
screened patients were not included and that approximately
one-quarter of patients received an intermediate-dose of
heparin. This may have blunted any differences in efficacy
and safety outcomes between the two treatment groups.
Furthermore, interpretation of these absolute risk differences should be done carefully given the adaptive, Bayesian nature of the study design rather than traditional 1:1
randomization as is often seen in most traditional randomized clinical trials. Patients at high risk of bleeding were
excluded from the study, which may partially explain the
low rate of major bleeding in the trial population. The definition of ‘major’ thrombotic events did not include deep vein
thrombosis; however, the addition of deep vein thrombosis
did not alter the results of the secondary outcome analysis.
There is also some question as to the value patients place on
the outcome of the absolute number of organ support-free
days versus any need for organ support, objective thromboembolic events, or overall survival. Finally, while large
and well conducted, there are concerns about the relatively
low rate of symptomatic thromboembolic events and lack of
mortality benefit.
In the RAPID COVID COAG study, 465 moderately
ill adult patients admitted with COVID-19 and elevated
D-dimer levels were randomized to receive therapeutic
intensity or standard dose prophylactic heparin.[15] Greater
than 90% of both treatment arms received LMWH (vs.
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unfractionated heparin). Patients were included if their
D-dimer level was > 2-times the hospital upper limit of normal (ULN) or if it was > 1-time the upper limit of normal
along with documented hypoxia. The primary endpoint of
death, invasive or non-invasive mechanical ventilation, or
ICU admission was not statistically different between the
two groups (16.2% versus 21.9% for therapeutic and standard intensity prophylaxis, respectively, OR 0.69, 95%
CI 0.43–1.10). Interestingly, the secondary outcome of
all-cause mortality was reduced with therapeutic intensity
prophylaxis (1.8% vs. 7.6%, OR 0.22, 95% CI 0.07–0.65)
while the VTE risk was low and similar in the two groups
(0.9% vs. 2.5% in the therapeutic and prophylactic groups,
respectively, OR 0.34, 95% CI 0.07–1.71). The rate of
major bleeding was similar in both groups (0.9% vs. 1.7%,
OR 0.52, 95% CI 0.09–2.85). VTE risk was low and similar
in the two groups − 0.9% versus 2.5% in the therapeutic and
prophylactic groups, respectively (OR 0.34, 95% CI 0.07–
1.71). This trial screened nearly 4000 patients to enroll and
randomize 465 patients. Strengths of this trial include the
use of blinded adjudication of outcomes and a set of study
endpoints that are patient centric. However, RAPID COVID
COAG was likely underpowered to detect a difference in
key outcome measures.
In the HEP-COVID trial, 257 patients admitted to the
hospital with COVID-19 and D-dimer levels > 4-times
the ULN were randomized to receive standard dose or
therapeutic intensity thromboprophylaxis with heparin
(mostly LMWH).[16] Patients were stratified at the time
Table 2 Suggested Criteria for Therapeutic Intensity Thromboprophylaxis for Moderately Ill Patients with COVID-19
Criteria for Potential Disease
Bleeding Risk Factors That
Progression
Must Not Be Present
Admitted for COVID-19 infection (not End stage renal disease on
an incidental finding)
dialysis
Supplemental oxygen requirement
Advanced liver disease or
cirrhosis
Severe thrombocytopenia
Elevated d-dimer (> 2–4 times ULN)
Use of dual antiplatelet
therapy
Need for therapeutic
anticoagulation (e.g., atrial
fibrillation, mechanical
heart valve)
Severe anemia
Contraindication to
heparin agents or Heparininducted thrombocytopenia
Recent bleeding
Bleeding disorder
To consider therapeutic intensity thromboprophylaxis for moderately
ill patients with COVID-19, they should meet all 3 criteria for disease
progression as well as not having any bleeding risk factors. Note that
the risk factors listed are not exhaustive

of randomization into ICU (32.8%) and non-ICU (67.2%)
cohorts. Use of therapeutic intensity thromboprophylaxis
reduced the primary efficacy outcome (arterial or venous
thromboembolism or death) significantly (28.7% versus
41.9%, RR 0.68, 95% CI 0.49–0.96), which was driven by
the non-ICU cohort (16.7% versus 36.1%, RR 0.46, 95% CI
0.27–0.81). Major bleeding was non-significantly elevated
in patients receiving therapeutic intensity thromboprophylaxis (4.7% versus 1.6%, RR 2.88, 95% CI 0.59–14.02)
overall but rates were similar among the non-ICU stratum
(2.4% versus 2.3%). Of note, this trial screened more than
11,000 patients to enroll 257, largely excluding patients
who did not meet criteria or lacked sufficiently elevated
D-dimer levels, which raises concerns about external validity. Furthermore, this study relied on local adjudication
of clinical events, which can lead to biased assessments
when treatment allocation is known. The analysis also
included asymptomatic VTE events identified on routine
lower extremity compression ultrasound study at hospital
day 10 ± 4 (or hospital discharge), the clinical importance
of which are unknown. However, symptomatic DVT was
significantly reduced (5.4% vs. 15.3%, RR 0.35, 95% CI
0.15–0.81) while symptomatic VTE was non-significantly
reduced (1.6% vs. 2.4%, RR 0.38, 95% CI 0.12–1.19).
In the ACTION trial, 615 patients randomized to treatment-dose rivaroxaban experienced similar risk of death,
duration of hospitalization, and duration of supplemental
oxygen as compared to prophylactic dose heparin.[17] The
composite thrombotic outcome (VTE, myocardial infarction, stroke, and major adverse limb events) was similar in
the two treatment groups (7% vs. 10%, RR 0.75, 95% CI
0.45–1.26). The outcome of ISTH-defined major bleeding
was higher in the rivaroxaban group than with prophylactic
dose heparin (8% vs. 2%, RR 3.64, 95% CI 1.61–8.27).
A few key points can be abstracted from these four published trials. First, use of therapeutic intensity non-heparin
thromboprophylaxis (e.g., rivaroxaban) did not demonstrate
benefit over standard dose thromboprophylaxis with heparin and increased the risk of major bleeding. Second, each
of the randomized trials used a different D-dimer threshold
for inclusion and/or analysis subgroups. Third, each of these
trials had strict inclusion and exclusion criteria that selected
for low bleeding risk patients, like most anticoagulant trials
for a new indication, suggesting that therapeutic intensity
anticoagulation, if used, should be applied only after weighing risks and benefits.

ULN – upper limit of normal
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Guidance Recommendation:
3) We recommend that all patients hospitalized
with COVID-19 receive at least standard dose
thromboprophylaxis.
4) In patients admitted to the hospital for indications
other than COVID-19 but incidentally found to have
COVID-19 infection, we recommend standard dose

thromboprophylaxis with LMWH or unfractionated
heparin (UFH) unless specific contraindications exist.
5) We suggest that clinicians consider the use of therapeutic intensity LMWH or UFH thromboprophylaxis for
non-critically ill patients at increased risk of disease
progression or thromboembolism and who are not high
risk for anticoagulant-related bleeding (Table 2).
6) We recommend that “intermediate” intensity thromboprophylaxis and/or antiplatelet agents only be used

Table 3 Dosing of COVID-19 Thromboprophylaxis in Hospitalized, Non-Pregnant Adults
Category
Enoxaparin
UFH
Standard-intensity
40 mg SQ daily
5000 units SQ
BID-TID
Renal impairment
CrCl 20–30 ml/min
30 mg SQ daily
5000 units SQ
BID-TID
CrCl < 20 ml/min[41]
Obesity
BMI > 40 kg/m2

Renal impairment + obesity
Therapeutic-intensity

1 mg/kg SQ BID

CrCl < 20 ml/min
Obesity
BMI > 40 kg/m2
Renal impairment + obesity
Extended duration

Renal impairment
CrCl < 30 ml/min
Obesity

Rivaroxaban
N/A

Usual dose with
caution
or use UFH
Use UFH

N/A

7500 units SQ
BID-TID[44]

7500 units SQ
daily[45]

N/A

7500 units SQ
BID-TID[44]
Per local IV
protocol

Use UFH

Use UFH
40 mg SQ
BID[42]
or
0.5 mg/kg SQ
daily[43]
Use UFH

Renal impairment
CrCl 20–30 ml/min

Dalteparin
5000 units SQ
daily

1 mg/kg SQ daily Per local IV
protocol
Use IV UFH per
local protocol

100 units/kg SQ
BID

N/A

Usual dose with
N/A
caution
or use IV UFH
per local protocol
Use IV UFH per
local protocol

N/A
(weight-based)
Use IV UFH per
local protocol
N/A

Per local IV
protocol
Per local IV
protocol
N/A

N/A
(weight-based)
Use IV UFH per
local protocol
N/A

N/A

N/A

N/A

N/A

Avoid use#

N/A

N/A

N/A

N/A
10 mg
PO daily
x 35–39
days[46, 47]

10 mg PO
daily x 35–39
days
*Dosing list is not exhaustive, but represents the most commonly used regimens in the cited COVID-19 clinical trials and in routine clinical
practice
#Rivaroxaban is FDA-approved for this indication in patients with CrCl ≥ 15 ml/min, but based on minimal evidence. Utilize with caution in
this population
Mg – milligrams, SQ – subcutaneous, BID – twice daily, TID – three times daily, UFH – unfractionated heparin, CrCl – creatinine clearance,
IV – intravenous, PO - oral
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in the setting of a clinical trial for hospitalized patients
with COVID-19.
Given that there are no head-to-head comparisons of
various heparin agents, use of either LMWH or UFH can be
considered for thromboprophylaxis. However, most heparin
used in the clinical trials was LMWH which also affords
less exposure and personal protective equipment utilization.
Suggested UFH and LMWH regimens for hospitalized
non-pregnant adults, including adjustments for renal impairment and obesity, are reflected in Table 3.
Whenever therapeutic intensity of UFH, LMWH, or
other anticoagulants are given for thromboprophylaxis and
not for treatment of presumed or confirmed thromboembolism, this should be clearly documented in the patient chart.

Critically Ill Hospitalized Patients with COVID-19
Three studies have examined the use of non-standard doses
of heparin for thromboprophylaxis in critically ill adult
patients with COVID-19 (online appendix). In the multiplatform trials, patients admitted to the ICU and requiring
organ support (e.g., high-flow oxygen, invasive ventilation,
vasopressor or inotropic support) did not experience benefit
when receiving therapeutic intensity thromboprophylaxis
(primarily LMWH) as compared to ‘usual care’ thromboprophylaxis (primarily LMWH).[18] Of note, use of “intermediate” intensity thromboprophylaxis was quite common
(51.7%) in the ‘usual care’ thromboprophylaxis group. Two
trials have evaluated intermediate versus standard dose
thromboprophylaxis in this population and failed to find a
statistically significant benefit. In the INSPIRATION trial,
patients admitted to the ICU did not experience benefit when
receiving intermediate-dose enoxaparin (1 mg/kg daily) as
compared to standard dose thromboprophylactic enoxaparin
(40 mg daily).[19] Finally, a small, multi-center randomized trial of 176 patients with COVID-19 admitted to the
ICU found a non-significant reduction in 30-day all-cause
mortality associated with intermediate-dose enoxaparin as
compared to standard dose thromboprophylactic enoxaparin
(15% vs. 21%, OR 0.66, 95% CI 0.30–1.45) with a low rate
of major bleeding (2% in each arm).[20].
Of note, approximately one-third of patients in the previously described HEP-COVID study required nonrebreather
oxygen mask or more intensive respiratory support.[16] The
primary efficacy endpoint (a composite of arterial thromboembolism, VTE, or death) was not significantly reduced
in the stratum of patients admitted to the ICU (51.1% vs.
55.3%, RR 0.92, 95% CI 0.62–1.39).

Guidance Recommendation:
7) We recommend that adult patients who are critically
ill at the time of hospitalization receive standard dose
thromboprophylaxis instead of intermediate- or therapeutic intensity thromboprophylaxis.
Suggested dosing regimens for hospitalized non-pregnant
adults, including adjustments for renal impairment and obesity, are reflected in Table 3.

Antiplatelet Use
Two trials have explored the use of antiplatelet therapy in
patients hospitalized with COVID-19. The RECOVERY
trial enrolled adult patients in the United Kingdom, Indonesia, and Nepal who were hospitalized with COVID-19.[21]
Patients were randomized to receive aspirin 150 mg daily or
usual care. Among the 14,892 patients who were randomized, the rate of 28-day all-cause mortality was similar in
the two groups (17% vs. 17%, RR 0.96, 95% CI 0.89–1.04).
There was also no significant difference in the median time
to discharge alive (8 vs. 9 days). In the ACTIVE-4a study,
562 non-critically ill patients hospitalized for COVID-19 in
Brazil, Italy, Spain, and the United States were randomized
to receive therapeutic intensity heparin plus a P2Y12 inhibitor (ticagrelor preferred) or therapeutic intensity heparin
alone.[22] The primary outcome of organ support-free days
was similar in both treatment groups (21 vs. 21, adjusted OR
0.83, 95% CI 0.55–1.25). There was also no difference in
the rate of survival to hospital discharge or major bleeding.
Guidance Recommendation:
8) Werecommendthat patients hospitalized with COVID19 do not receive antiplatelet therapy (e.g., aspirin,
P2Y12 inhibitor) for the specific purpose of preventing
thromboembolism or COVID-19 disease progression.

Hospital Transitions of Care
Many patients who are hospitalized for COVID-19 infection will require transfers of care between the floor and
ICU and vice versa. No studies have specifically compared
different anticoagulation strategies when patients initially
admitted to one unit (e.g., floor) require a chance in level
of care (e.g., transfer to an ICU). The study protocols of the
various randomized trials generally recommended patients
remain on their initial intensity of anticoagulation even
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when transferring between different levels of care (e.g.,
floor to ICU) for up to 14 days or until recovery since the
patients were enrolled and randomized shortly after hospital admission.[14, 18] Any decisions to use higher intensity
anticoagulation should be clearly documented to provide
guidance on approaches to post ICU management. Furthermore, there is no prospective clinical evidence to support
the use of serial D-dimer testing to guide the intensity of
antithrombotic therapy.
Guidance Recommendation:
9) We suggest that adult patients admitted to the hospital
for COVID-19 remain on the intensity of VTE thromboprophylaxis that was initiated at hospital admission as
long as their bleeding risk is not significantly elevated.
Thus, a moderately-ill patient with COVID-19 admitted to
the ward and started on therapeutic intensity thromboprophylaxis should continue therapeutic intensity thromboprophylaxis when transferring to the ICU. The dose should be
reduced to standard dose thromboprophylaxis when clinically necessary based on bleeding risk.
Similarly, patients initially admitted to the ICU for organ
support and started on standard dose thromboprophylaxis
should continue standard dose thromboprophylaxis when
they transfer to the floor.
Patients should receive therapeutic intensity anticoagulation if a thromboembolic event is confirmed or highly suspected, and bleeding risk is not prohibitively high.

Post-hospital Period
Observational studies have reported conflicting results
regarding post-hospital VTE risk. In most reports, the
observed risk of VTE was similar to patients without
COVID-19.[9, 23–25] However, in one report, the risk of
post-hospital VTE was elevated compared to patients without COVID-19.[26] Most recently, the MICHELLE trial
randomized 320 patients hospitalized for COVID-19 who
were receiving standard dose thromboprophylaxis during
their admission and were considered at increased risk for
post-discharge events, with an IMPROVE VTE score of ≥ 4
or an IMPROVE VTE score of 2–3 plus a D-dimer > 500
ng/ml at discharge.[27] Patients at increased risk of bleeding, such as those with bleeding in prior 3 months, on dual
antiplatelet therapy or with chronic kidney disease, were
excluded. Only 11 patients with creatinine clearance 30–50
ml/min were included in the study. Enrolled subjects were
randomized to rivaroxaban 10 mg by mouth daily for 35 days
or no post-discharge thromboprophylaxis. Post-hospital

13

thromboprophylaxis with rivaroxaban reduced the primary
composite outcome of symptomatic venous or arterial
thromboembolism, VTE-related death, bilateral VTE, myocardial infarction, non-hemorrhagic stroke, major adverse
limb event or cardiovascular death compared to no intervention (3.14% VS. 9.43%, RR 0.33, 95% CI 0.13–0.90). There
were no major bleeds in either group. However, it should
be noted that the MICHELLE trial screened 997 patients in
order to enroll 320, suggesting that post-hospital extended
thromboprophylaxis is not appropriate for all patients hospitalized with COVID-19. Note that the IMPROVE VTE
score used in the MICHELLE trial gave 1 point for immobilization (confined to bed or chair with or without bathroom
privileges) that lasted ≥ 1 day. This contrasts with the original IMPROVE VTE score which defined immobilization as
≥ 7 days immediately prior to and including hospitalization.
[28].
Guidance Recommendation:
10) We recommend that clinicians not routinely use posthospital thromboprophylaxis after discharge following
hospitalization for COVID 19 for all patients, including
those who may have received therapeutic intensity anticoagulation for thromboprophylaxis.
11) We suggest post-hospital thromboprophylaxis with
rivaroxaban 10 mg daily for 35 days following a hospitalization for COVID-19 may be considered in select
patients at increased risk of thromboembolism (e.g.,
IMPROVE VTE score ≥ 4 or score 2–3 with elevated
D-dimer at hospital discharge) and not at increased risk
of bleeding regardless of the intensity of their inpatient
thromboprophylaxis.
12) We recommend clear documentation and communication of indication and intended duration of post-hospital thromboprophylaxis to providers and next care
settings to avoid unnecessarily prolonged exposure to
anticoagulation.

Thromboprophylaxis for Pediatric Patients
with COVID-19
In general, children with SARS-CoV2 have much milder
infections compared to adults, rarely requiring hospitalization. However, more severe acute COVID-19, characterized
by the typical respiratory phenotype, does occur and is more
common in children with underlying medical conditions.
Children may also develop a post-infectious multisystem
inflammatory syndrome (MIS-C) that manifests with fever,
cardiovascular shock, hyperinflammation and multi-system
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involvement. Rates of thrombotic complications in children
with COVID-19 and MIS-C have not been well established,
but a multi-center retrospective cohort study reported radiologically confirmed venous or arterial thrombosis in 2.1%
(9/426) and 6.5% (9/138) of children hospitalized with acute
COVID-19 and MIS-C respectively. Risk factors for thrombosis included age > 12 years, cancer, presence of a central
venous catheter and MIS-C.[29] D-dimer > 5x upper limit of
normal was also a risk factor in the univariate model. The
mortality rate in children hospitalized with COVID-19 or
MIS-C was 2.3%, but was 28% in those with thrombosis,
suggesting thrombosis may contribute to mortality. Similar to what has been reported in adult studies, a significant
proportion of VTE (71%) occurred in children who were
already receiving anticoagulant prophylaxis. There was
wide variation in the intensity of anticoagulation used for
thromboprophylaxis among centers; no patient developed a
post-discharge VTE.[30].
Randomized trials evaluating the efficacy and intensity of anticoagulant prophylaxis in COVID-19 pediatric
patients have not yet been conducted, although prophylaxis
is frequently used in tertiary care centers. In the interim, we
suggest adhering to the Pediatric/Neonatal Hemostasis and
Thrombosis Scientific Subcommittee of the International
Society on Thrombosis and Hemostasis expert-consensusbased guidance for thromboprophylaxis in this population.
[31].

Guidance recommendations:
13) We suggest that clinicians consider thromboprophylaxis
with twice daily LMWH (e.g., enoxaparin 0.5 mg/kg
BID) targeted to an anti-Xa activity level of 0.2 to < 0.5
IU/ml (in combination with mechanical prophylaxis
when feasible) in pediatric patients hospitalized with
acute COVID-19 or MIS-C and one or more additional
risk factors associated with hospital-acquired VTE (e.g.,
central venous catheter, age > 12 years, immobility,
mechanical ventilation, history of VTE, obesity, active
malignancy, etc.) OR markedly elevated D-dimer, as
long as the patient is not high risk for bleeding.
14) We recommend against thromboprophylaxis in hospitalized children who are incidentally found to have
asymptomatic SARS-CoV-2 in the absence of other
VTE risk factors that would normally merit prophylaxis.
15) Because of very limited published evidence, we suggest
that post-discharge thromboprophylaxis be considered
on a case-by-case basis only in highly select pediatric
patients with multiple ongoing risk factors.

The expert panel acknowledged the lack of pediatric data to
support these recommendations, particularly with regard to
intensity of anticoagulation, and called for additional investigation in this area.

Thromboprophylaxis in Obstetric Patients
with COVID-19
Randomized trials of thromboprophylaxis in adult COVID19 patients have excluded pregnant women. Thus, there is no
high-quality evidence to inform best approaches in COVID19 positive obstetric patients. Pregnancy itself is a hypercoagulable condition and paired with acute illness, reduced
mobility and dehydration may place pregnant women at significant risk of VTE. Retrospective analyses have reported
thromboembolic complications in pregnant women with
COVID-19, but it is unknown if the incidence is higher than
in non-pregnant women. Routine use of thromboprophylaxis for pregnant women who are COVID-19 positive but
do not require hospitalization is not required.[32] However,
thromboprophylaxis should be considered for hospitalized
pregnancy according to existing population-specific societal
guidelines, taking into consideration patient characteristics
(e.g., renal function, obesity) and obstetrical status (e.g.,
trimester, timing relative to expected labor and delivery).
Additionally, close collaboration with obstetric and anesthesiology colleagues is recommended in the event of spontaneous delivery and/or need for epidural anesthesia during
hospitalization. For pregnant women already receiving prophylactic or therapeutic anticoagulation who are admitted to
the hospital for COVID-19, these therapies should be continued during the admission and for the appropriate duration
after discharge. DOACs should be avoided in pregnancy as
they have not been adequately studied and may cause fetal
harm. There is no data to suggest need for routine thromboprophylaxis beyond hospitalization for COVID-19, and use
should be limited to pregnant women who otherwise meet
non-COVID-19 criteria for extended obstetric prophylaxis
as per societal guidelines.[33].

Guidance recommendations:
16) We recommend against routine thromboprophylaxis
for pregnant women found to be COVID-19 positive
and not requiring admission to the hospital. Patients
should be encouraged to stay hydrated and ambulate at
home.
17) For pregnant women requiring hospitalization for
COVID-19, we recommend use of thromboprophylaxis in accordance with existing obstetric guidelines
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for non-COVID-19 positive women.[33–36] Readers
are referred to those population-specific resources for
thromboprophylaxis dosing recommendations that take
into consideration trimester, as well as ante- and postpartum needs.
18) For pregnant women already receiving anticoagulant
prophylaxis or treatment prior to hospital admission for
COVID-19, we recommend continuing those therapies
during admission and beyond if indicated.
19) We suggest against routine post-discharge prophylaxis
for COVID-19 positive obstetric patients unless they
otherwise meet criteria for extended obstetric prophylaxis for non-COVID populations.
Thromboprophylaxis for Moderately Ill Patients in
Long-term Care Facilities Who Are Not Transferred to
the Hospital.
Many patients who reside in long-term care facilities
have multiple comorbidities and advanced age which presents increased risk for thrombotic complications during an
acute, infectious illness such as COVID-19. When aligned
with a patient’s goals of care, similar approaches to thromboprophylaxis can be used in the long-term care setting as
would be used in the acute hospital setting if the patients is
otherwise ill enough to warrant hospital admission.
Guidance recommendation:
20) We suggest that patients who reside in long-term care
settings who are ill enough with COVID-19 to be
considered for hospital admission but remain in the
long-term care facility be offered standard intensity
thromboprophylaxis (Table 3) for up to 10–14 days only
if this aligns with their goals of care.

Thromboprophylaxis in Patients with Known
Thrombophilia
Patients with known thrombophilia are at increased risk for
VTE from any acute medical hospitalization. However, data
regarding any differential risk of thromboembolism while
hospitalized with COVID-19 is lacking.

Guidance Recommendation:
21) We recommend that all adult patients with a known
thrombophilia receive at least standard intensity thromboprophylaxis when hospitalized for COVID-19, unless
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already on chronic therapeutic-intensity anticoagulation
for the thrombophilia.
The presence of a known thrombophilia (and in the absence
of chronic therapeutic-intensity anticoagulation for the
thrombophilia) may sway the risk-benefit balance toward
the use of therapeutic-intensity thromboprophylaxis in adult
hospitalized medical patients with moderate COVID-19 illness as long as the risk of bleeding is not prohibitively high.
Patients with a known thrombophilia who are admitted to
the hospital with critically ill COVID-19 should typically be
treated with standard thromboprophylaxis in a similar fashion to critically ill patients without thrombophilia.
Patients with a known thrombophilia that are not otherwise on chronic therapeutic-intensity anticoagulation may
be candidates for post-hospital thromboprophylaxis if they
meet the inclusion criteria stated above.

Management of Patients on Anticoagulation
Prior to Admission for COVID-19
Patients who use anticoagulation for chronic thromboembolic conditions (e.g., atrial fibrillation, VTE, mechanical
valve) continue to be at risk of their baseline thromboembolic condition during their hospitalization for COVID-19.
However, during hospitalization, they may also develop
transient or long-standing bleeding risk factors (e.g., acute
renal failure, need for invasive procedures, drug-drug interactions) that require adjustment to the anticoagulation treatment strategy.

Guidance recommendation:
22) We recommend that patients who are admitted to the
hospital for COVID-19 infection be assessed for the use
of ongoing outpatient anticoagulation.
23) We recommend that the outpatient anticoagulation
regimen be continued during the hospitalization for
COVID-19 unless there are conditions that will preclude
safe use (e.g., acute renal failure, anticipated invasive
procedures, significant drug-drug interactions). Therapeutic or prophylactic UFH or LMWH may be substituted according to the clinical scenario. Dosing intensity
of UFH or LMWH should take into consideration the
underlying non-COVID indication for anticoagulation
as well as COVID-related thromboprophylaxis needs as
described in the above recommendations.
24) We recommend that patients who were receiving
reduced dose or very low dose anticoagulation (i.e.,
rivaroxaban 2.5 mg twice daily) prior to admission and
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who are hospitalized for COVID-19 receive either standard dose or therapeutic intensity thromboprophylaxis
with LMWH or UFH as clinically appropriate (see recommendations above).

VTE Treatment
VTE guidelines favor a finite duration of anticoagulation
therapy (e.g., 3–6 months) for VTE provoked by non-surgical transient risk factors such as medical illness, while also
favoring ongoing therapy in the setting of significant persistent risk factors.[37, 38] Whether the risk of VTE recurrence
among hospitalized patients with COVID-19 who develop
VTE differs significantly from that of VTE provoked by
other medical illness is not well established. Experience
would suggest that the number of patients experiencing
continued debility beyond three months is not insignificant.
As such, while a finite duration of anticoagulation therapy
should be the goal, having a low threshold for continuing
therapy and reassessing patients’ recovery at regular intervals is a reasonable approach. Recurrence risk is likely low
once the COVID-19 infection resolves and patients return to
their baseline level of health.[39] Initial therapy likely will
include LMWH or UFH, but can transition to DOAC therapy once the patient stabilizes prior to hospital discharge.

Guidance Recommendation:
25) We recommend that most patients who are diagnosed
with VTE while hospitalized for COVID-19 receive
anticoagulation for a minimum of three to six months,
in accordance with recent guidelines for VTE with a
transient provoking risk factor.[37, 38].
26) We suggest a finite course of anticoagulation (e.g., 3–6
months) rather than continuing anticoagulation longterm for secondary prevention in most patients with
COVID-19 associated VTE. The duration should be a
minimum of three months and defined by the presence
or absence of persistent risk factors and the patients’
return to their baseline functional status.

Vaccination for patients on anticoagulation
or prior VTE/thrombophilia
Vaccination is the leading strategy to control the COVID-19
pandemic. With significant protection against both infection and severe illness, major public health organizations
strongly recommend that all eligible people are vaccinated
against COVID-19. Given rare reports of both typical and

unusual site thromboembolism following COVID-19 vaccination, many have wondered about the safety of COVID-19
vaccination for patients with a history of thromboembolism,
thrombophilia, or current use of anticoagulation. Given the
strong association between COVID-19 infection and thromboembolism, the rare occurrence of usual or unusual site
thrombosis following COVID-19 vaccination is greatly outweighed by the benefit of preventing COVID-19 infection.
[8] Furthermore, the occurrence of unusual site thromboembolism associated with thrombocytopenia (known as Vaccine-induced Thrombosis and Thrombocytopenia [VITT] or
the Thrombosis and Thrombocytopenia Syndrome [TTS]) is
driven by an immune-mediate process that is not linked to a
history of thrombosis, thrombophilia, or current anticoagulant use.[40] A prior history of VTE or current use of anticoagulation should not influence the selection of one type of
COVID-19 vaccine over another. There is no role for specific thromboprophylaxis (anticoagulation or antiplatelet)
prior to receiving the COVID-19 vaccine.

Guidance Recommendation:
27) We recommend that all patients with a history of thromboembolism, thrombophilia, or current use of anticoagulation receive COVID-19 vaccination if eligible.
28) We recommend that anticoagulation not be withheld
for vaccine administration.
29) If a patient currently uses anticoagulant therapy, we
recommend that pressure be held at the site of vaccine
administration for 5 min to minimize any risk of injection-related bleeding.
30) We recommend that standard warfarin monitoring
schedules not be altered in relation to vaccine administration for most patients. Individual patients experiencing significant symptoms, such as fever or dietary
disruption, should contact their prescriber to determine
if additional INR follow up is warranted.
Guidance recommendations for patients with thrombophilia, those in long-term care facilities, those using anticoagulation prior to COVID-19 hospitalization, and those with
prior VTE considering COVID-19 vaccination are based on
expert consensus given the lack of prospective clinical trial
data or high-quality observational data.

Conclusions
While the guidance statements above are based on the best
available evidence at the current time, there are multiple trials underway that may refine the recommended approach to
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thromboprophylaxis in COVID-19. Clinicians are encouraged to use the rapidly emerging evidence in concert with
expert guidance to make clinical management decisions for
individual patients. Online resources, such as the Anticoagulation Forum Centers of Excellence, receive timely updates
to provide clinicians reliable resources as new data emerge.

use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
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